Joseph Brewer, MD

ISEAI Honorary Member

Joseph Brewer, MD is an infectious disease specialist in Kansas City, Mo. Dr. Brewer is in private practice with Plaza Infectious Disease and also is a consulting physician at St. Luke’s Hospital of Kansas City. He is an assistant clinical professor of medicine at the University of Missouri – Kansas City School of Medicine. Dr. Brewer is involved in clinical teaching at St. Luke’s and UMKC. He has been in practice for over 30 years including clinical practice of infectious disease, teaching responsibilities and clinical research. Dr. Brewer has had a long- standing interest in chronic illness patients including chronic fatigue syndrome and Lyme disease. Since 2012, Dr. Brewer has been studying the role of toxic mold and mycotoxins in chronic illness. This research has resulted in several new findings. Dr. Brewer and his colleagues have published several papers on the subject of toxic mold.

Learn more:,

ISEAI 2019 Conference Lecture

Friday, May 3 1:30 pm – 2:30 pm
Current Approaches to Treatment of Mycotoxin Illness

Lecture Highlights:

  • Mycotoxins are commonly found in chronic illness patients (e.g. CFS, FM)
  • Chronic illness patients with mycotoxins frequently report current / ongoing environmental exposure, past exposure or both
  • In patients with past exposure (with or without current exposure), there may be mycotoxins produced from “internal” sources of which the sinuses are the most likely
  • Intranasal antifungal therapy (e.g. amphotericin B, itraconazole, nystatin) may be effective therapies for the mold in the sinuses and lead to clinical improvements in these patients
  • Intranasal therapy with colloidal silver may also be effective therapy
  • Systemic antifungal therapy could be considered but is usually not necessary
Joseph Brewer, MD